Clinical Trial Update: GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a GLP-1 analogue to prevent progression of cerebral small vessel disease is currently recruiting in Hong Kong.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Small Vessel Disease

Drugs mentioned

• GLP-1 analogue (GLP-1 analogue)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Cerebral Small Vessel Disease | Phase 2 | Status: RECRUITING